What is an immune reset and how can it transform the treatment of autoimmune diseases?? Our CEO Fred Aslan answered this question and more in his recent interview with PharmaShots. ???????????? ??????????: A groundbreaking approach that involves deep B-cell depletion and reconstitution with a na?ve phenotype, potentially leading to drug-free remission. ????????????'?? ???? ???????? ??????????????: AlloNK?, an allogeneic NK cell therapy, aims to enhance the ADCC effect of mAbs to provide potent B-cell depletion with a favorable safety profile, designed for outpatient settings. ?????? ????????????????????: Initial clinical data expected in 1H 2025. Learn more here: https://lnkd.in/g-Bg9cRx #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
Artiva Biotherapeutics
生物技术研究
San Diego，California 9,989 位关注者
We are dedicated to making safe and effective cell therapies accessible to any cancer patient who may benefit.
关于我们
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK?, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
- 网站
-
https://www.artivabio.com
Artiva Biotherapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2019
- 领域
- cell therapy、cancer、nk cells、nk cell therapy和car-nk
地点
-
主要
获取路线
5505 Morehouse Drive, Suite 100
US，California，San Diego，92121
Artiva Biotherapeutics员工
动态
-
Artiva Biotherapeutics reports third quarter 2024 financial results and recent business highlights. Read the press release for more details: https://lnkd.in/gu-_jaNX #ARTV #Q3Earnings #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #celltherapy
-
Artiva’s CEO Fred Aslan and Neha Krishnamohan, CFO & EVP, Corporate Development, will be at Jefferies London Healthcare Conference 2024 discussing how AlloNK? can expand cell therapy access for the treatment of autoimmune disease. Artiva’s fireside chat will take place Wednesday, November 20, at 3:30pm GMT. See more details in the press release, including a link to the webcast to watch live or via replay: https://lnkd.in/gyUENcFv #JefferiesHealthcare #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
-
-
Nicholas Veomett, Vice President of Corporate Development & AlloNK? Program Lead at Artiva Biotherapeutics, will be presenting at the ???????????????????????? ???????????? & ?????????????? ???????????????????? ???????????? on November 12th at 3 PM ET in Boston. His talk, “?????????????????? ???????????? ???? ???????? ?????????????? ???? ???????????????????? ?????????????? ???????? ??????-??????-?????????? ????????????,” will cover: ? AlloNK’s use as a cryopreserved, non-genetically modified NK cell therapy, combined with monoclonal antibodies in autoimmune disease ? Promising clinical data from aggressive non-Hodgkin lymphoma patients, supporting outpatient administration potential ? Artiva’s robust manufacturing process, yielding over thousands of doses of AlloNK from each cord blood unit ? Updates on two active clinical trials investigating AlloNK in autoimmune disease See the conference agenda here: https://lnkd.in/dixhGvwM #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #celltherapy
-
-
Artiva Biotherapeutics is pleased to welcome Alison Moore, Ph.D., to our Board of Directors. With more than 25 years of executive experience in biotech and deep cell therapy manufacturing experience, Dr. Moore will bring an important perspective as we advance our AlloNK pipeline in the clinic and work to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Read more here: https://lnkd.in/grwFkjbh ?#AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
-
-
Next week, our CFO & EVP, Corporate Development, Neha Krishnamohan will be at the ???????? ?????? ???????? ?????????????? ???? ?????? ???????? next week presenting on the potential of NK cells as an allogeneic cell therapy approach in autoimmune disease. See the agenda here: https://lnkd.in/eiUpMy4 #CGMesa24 #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis
-
-
We were honored to present at the ???????????? ???????? ???????????? ???????????????????? ???????????????????? in New York last week and discuss how allogeneic NK cell therapies can transform the treatment of autoimmune diseases. ?? If you missed it, watch the webcast here: https://lnkd.in/gnjFAMS2 #CantorHCC #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #biotech #InvestorEvent
-
-
Our CEO Fred Aslan will be presenting at the ???????????? ???????? ???????????? ???????????????????? ????????????????????. Join for a Fireside Chat on ?????????????????? ???????? ???? ??:???? ???? ?????? to learn more about the opportunity for allogeneic NK cell therapies to transform the treatment of autoimmune diseases. ??? Read the press release for more details: https://lnkd.in/gvbAWyDx ?? Watch the webcast here: https://lnkd.in/gDkVQxAJ #CantorHCC #AlloNK #NKcell #NKcells #NKcelltherapy #clinicaltrials #autoimmunedisease #autoimmunity #immunology #autoimmune #lupus #lupusnephritis #biotech #InvestorEvent
-
-
Artiva Biotherapeutics announces strong Q2 2024 financial results and recent business milestones. We’re excited to share our progress in Q2 2024, marked by important achievements: ?? Successfully completed an upsized $179.0 million IPO, strengthening our balance sheet ?? Initiated treatment for the first patient in an investigator-initiated basket trial of AlloNK? exploring multiple autoimmune indications ?? Treated the first patient in our Phase 1/1b trial targeting class III/IV lupus nephritis (LN) and expanded the trial to include patients with systemic lupus erythematosus (SLE) without kidney involvement At Artiva, we remain committed to advancing innovative NK cell therapies for patients with serious unmet medical needs. Read the full release here: https://lnkd.in/gxskVSPd #biotech #biopharma #healthcareinnovation #ArtivaBiotherapeutics #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer
-
Our CEO Fred Aslan spoke with Brian Orelli, PhD, of BiotechTV about our recent #IPO, the potential of NK cell therapy to achieve deep B cell depletion to treat autoimmune disease, and how Artiva’s platform can make these cell therapies broadly accessible to patients who need them. Watch below or check out the interview here: https://lnkd.in/gFpZ5DNX #biotech #AlloNK #lupus #NKcell #NKcells #NKcelltherapy #autoimmunedisease #cancer
?????????????? ????????: Checking in with Artiva Biotherapeutics' CEO Fred Aslan after the NK cell focused company's $167 million IPO. He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Full video: https://lnkd.in/gFpZ5DNX BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent